Profiling blood biomarkers in colorectal cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates patients with colorectal cancer (CRC) by conducting longitudinal plasma ctDNA biomarker profiling alongside their standard treatment and disease monitoring. Participants will provide blood samples during routine surveillance visits to assess the presence of circulating tumor DNA (ctDNA). The study aims to enhance understanding of CRC progression and treatment response through genomic profiling. It involves multiple centers to gather diverse data on patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Known or suspected colorectal adenocarcinoma (Stage I to IVA disease)
* Planning to undergo or has undergone a surgical resection for suspected adenocarcinoma of the colon or rectum with curative intent.
* 18 years old or older
* Willing and able to provide informed consent
* Willing to have additional blood samples collected during routine surveillance visits

Exclusion Criteria:

* Not willing to have additional blood samples collected
* Pathology that is not consistent with colorectal adenocarcinoma

Where it's running

• Mercy Clinic Oncology - Fort Smith
  Fort Smith, Arkansas, United States Recruiting
• MemorialCare
  Fountain Valley, California, United States Recruiting
• The Center for Cancer and Blood Disorders
  Bethesda, Maryland, United States Recruiting
• Mercy Clinic Oncology and Hematology - Joplin
  Joplin, Missouri, United States Recruiting
• Mercy Clinic Cancer and Hematology - Chub O'Reilly Cancer Center
  Springfield, Missouri, United States Recruiting
• Washington University School of Medicine
  St Louis, Missouri, United States Recruiting

Study contacts

• Principal investigator: Kristiyana Kaneva, MD, MS — Tempus AI, Inc.
• Study coordinator: CRC Surveillance Study
• Email: gemini-crc@tempus.com
• Phone: (833) 514-4187

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Knife-assisted full-thickness resection for rectal lesions in a multicenter setting

  A multicenter study tests knife-assisted full-thickness resection (kFTR) to remove rectal lesions in adults and see how well it works and how safe it is.

  Recruiting University Hospital, Ghent · Ghent · NCT07923682

• Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model

  This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.

  Recruiting Peking Union Medical College Hospital · Ningbo, Zhejiang · NCT07919418

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery

  Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.

  Recruiting Semmelweis University · Budapest · NCT07896174

• Liver transplantation for colorectal cancer with liver metastases

  This study follows adults with stage IV colorectal cancer whose disease is limited to the liver and who are getting a liver transplant as part of their cancer care to see how they fare over time.

  Recruiting Pontificia Universidad Catolica de Chile · Santiago, Santiago Metropolitan · NCT07884110

• LTZ-232: a first-in-human test in advanced colorectal and other solid tumors

  A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.

  Recruiting Phase 1 LTZ Therapeutics, Inc. · Scottsdale, Arizona · NCT07878988

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.